BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 4
• 5
• 6
• 7
• 8
• 11
• 12
• 13
• 14
• 15
• 18
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28
• 29

• 

  Manufacturing

  Novo-Catalent Deal Represents ‘Defining Moment’ for CDMO Sector

  Novo Holdings’ acquisition of Catalent has ignited concerns from industry stakeholders, who fear that the consolidation could limit competition, but there is also the possibility that the deal could represent an opportunity for smaller-scale CDMOs to find new partners.

  November 13, 2024

   · 

  4 min read

   · 

  Ben Hargreaves
• 

  Podcast

  AbbVie’s Surprise Schizophrenia Flop, AstraZeneca’s China Drama, Hope in Huntington’s, More

  A tale of two multi-billion schizophrenia deals, AstraZeneca touts strong sales while deflecting questions about an investigation into China exec, the Huntington’s pipeline builds momentum and layoffs continue with Sana Biotechnology and 23andMe.

  November 13, 2024

   · 

  1 min read

   · 

  Heather McKenzie
• 

  Business

  5 Reasons Biogen’s Shares Have Dropped 36% in 2024

  A slow launch for Alzheimer’s medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a few of the factors that have sent Biogen’s shares down this year.

  November 13, 2024

   · 

  7 min read

   · 

  Annalee Armstrong
• 

  Obesity

  Amgen Suffers Surprise Blow as New Bone Density Safety Concerns for MariTide Surface

  Cantor Fitzgerald analyst Olivia Brayer found supplementary bone mineral density data for Amgen’s obesity candidate MariTide that could point to a potentially greater fracture risk than previously revealed, but some other analysts view the findings as a nonissue.

  November 13, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Mergers & acquisitions

  BioNTech Takes Aim at Keytruda With Up to $950M Biotheus Buy

  The acquisition will give BioNTech full ownership of an investigational bispecific antibody targeting the PD-L1/VEGF-A pathways, a hot area in oncology that could potentially replace standard checkpoint inhibitors for cancer treatment.

  November 13, 2024

   · 

  3 min read

   · 

  Tristan Manalac
• 

  FDA

  Kezar’s Autoimmune Drug Hit With Second FDA Clinical Hold in as Many Months

  Following patient deaths in a lupus trial that led to the termination of that program, Kezar’s autoimmune candidate zetomipzomib faces a partial clinical hold barring four trial participants from continuing treatment in the open-label portion of the trial, though the trial itself will continue as planned.

  November 13, 2024

   · 

  2 min read

   · 

  Heather McKenzie
• 

  Opinion

  Don’t Import Bad Policy Ideas on Drug Pricing

  Suggestions that the U.S. should emulate other countries on drug price controls or patents obscure how our present policies have allowed drug development to flourish.

  November 13, 2024

   · 

  4 min read

   · 

  Kirsten Axelsen
• 

  Cancer

  Syros Crashes Over 90% on Late-Stage MDS Fail, Loan Default

  With the Phase III failure, Syros will discontinue the study of tamibarotene for myelodysplastic syndrome and will default on its loan from Oxford Finance LLC.

  November 13, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  Fledgling Obesity Biotech Metsera Raises Another $215M for Long-Acting GLP-1

  Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a continued appetite for these drugs.

  November 13, 2024

   · 

  2 min read

   · 

  Kate Goodwin
• Press Releases

  Nippon Shinyaku and Atsena Therapeutics enter into an Exclusive Strategic Collaboration for ATSN-101 in the U.S. and Japan

  November 13, 2024

   · 

  5 min read